The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis

Review article: sarcopenia in cirrhosis - aetiology, implications and potential therapeutic interventions

(2016) M. Sinclair et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice

(2016) Yanbo Fan et al.   GASTROENTEROLOGY

Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study

(2016) Jeffrey Cui et al.   HEPATOLOGY

Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes

(2016) Mohammed Eslam et al.   HEPATOLOGY

Inactivation ofTm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins

(2016) Eriks Smagris et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease

(2016) Salvatore Petta et al.   JOURNAL OF HEPATOLOGY

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

(2016) Khaled Thabet et al.   Nature Communications

Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes

(2016) Silvia Sookoian et al.   Scientific Reports

The dual and opposite role of theTM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis

(2015) Carlos J. Pirola et al.   HEPATOLOGY

Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients

(2015) Marta Milano et al.   HEPATOLOGY

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

(2015) Paola Dongiovanni et al.   HEPATOLOGY

Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity

(2015) Silvia Sookoian et al.   HEPATOLOGY

TM6SF2rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C

(2015) Salvatore Petta et al.   LIVER INTERNATIONAL

TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism

(2015) Nicola Coppola et al.   LIVER INTERNATIONAL

A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis

(2015) Stephan Buch et al.   NATURE GENETICS

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis

(2015) Paola Dongiovanni et al.   Biomed Research International

The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis

(2014) Amit G Singal et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases

(2014) Francesco Negro   JOURNAL OF HEPATOLOGY

Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk

(2014) Oddgeir L Holmen et al.   NATURE GENETICS

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

(2014) Julia Kozlitina et al.   NATURE GENETICS

TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content

(2014) H. Mahdessian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New horizons in hepatitis C antiviral therapy with direct-acting antivirals

(2013) Alessio Aghemo et al.   HEPATOLOGY

Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?

(2012) David van der Poorten et al.   HEPATOLOGY

Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C

(2011) Eric Trépo et al.   HEPATOLOGY

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

(2011) Francesco Marabita et al.   HEPATOLOGY

HCV and the hepatic lipid pathway as a potential treatment target

(2011) Margaret F. Bassendine et al.   JOURNAL OF HEPATOLOGY

Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C

(2010) Luca Valenti et al.   HEPATOLOGY

Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement

(2009) Julian Little et al.   HUMAN GENETICS

Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C

(2008) Ian Homer Y. Cua et al.   HEPATOLOGY